You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 7,611,712

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,611,712

Title:	Immunogenic compositions capable of eliciting Th1 immune responses comprising an HIV-1 MA myristate binding site polypeptide
Abstract:	The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The present invention contemplates three categories of embodiments: protein or protein fragments (SEQ ID NO: 1), messenger RNA, or DNA/RiNA (SEQ ID NOS:2-3). DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.
Inventor(s):	Karp; Nelson M. (Virginia Beach, VA)
Assignee:	Karp; Nelson M. (Virginia Beach, VA)
Application Number:	10/971,229
Patent Claims:	1. An immunogenic composition comprising, an HIV-1 MA polypeptide myristate binding site said polypeptide consisting of SEQ ID NO.: 1, and a pharmaceutically acceptable carrier, wherein said composition is capable of inducing a Th1 immune response to HIV-1. 2. A composition according to claim 1, in which said binding site is expressed by a recombinant carrier. 3. A composition according to claim 2, wherein said recombinant carrier is a virus. 4. A composition according to claim 3, wherein said virus is a herpes virus. 5. A composition according to claim 4, wherein said herpes virus is Epstein Barr virus. 6. A composition according to claim 3, wherein said virus is a poliovirus. 7. A composition according to claim 3, wherein said composition has been heated with neuraminidase, trypsin, or other appropriate enzyme to remove sialic acid. 8. A composition according to claim 2, wherein said recombinant cater is bacteria. 9. A composition according to claim 8, wherein said bacteria is Bacillus Calmette-Guerin. 10. A composition according to claim 8, wherein said bacteria is Listeria monocytogenes. 11. A composition according to claim 8, wherein said composition has been treated with neuraminidase, trypsin, or other appropriate enzyme to remove sialic acid. 12. A composition according to claim 2, wherein said recombinant cater is yeast. 13. A composition according to claim 12, wherein said yeast is Saccharomyces cerevisiae. 14. A method of inducing a Th1 immune response in a host comprising, administering to said host an immunogenic composition comprising an HIV-1 MA polypeptide myristate binding site said polypeptide consisting of SEQ ID NO.: 1, and a pharmaceutically acceptable carrier, wherein said composition induces a Th1 anti-HIV immune response. 15. A method according to claim 14, wherein the composition is administered, orally, transbucally, transmucosally, sublingually, nasally, rectally, vaginally, intraocularly, intramuscularly, intralymphatically, intravenously, subcutaneously, transdermally, intradermally, intra tumor, topically, transpulmonarily, by inhalation, by injection, or by implantation. 16. A method according to claim 14, wherein the composition is administered, by capsule, gelcap, tablet, enteric capsule, encapsulated particle, powder, suppository, injection, ointment, cream, implant, patch, liquid, inhalant, or spray. 17. A composition according to claim 1, wherein said composition is combined with an immune stimulant. 18. A composition according to claim 17, wherein said immune stimulant is an adjuvant. 19. A composition according to claim 17, wherein said immune stimulant comprises polysaccharides composed of at least one mannose in a form capable of binding to said composition. 20. A composition according to claim 17, wherein said immune stimulant comprises teichoic acid in a form capable of binding to said composition. 21. A composition according to claim 17, wherein said immune stimulant comprises zymosan in a form capable of binding to said composition. 22. A composition according to claim 17, wherein said immune stimulant comprises cryptococcus neoformans serotype C having a polysaceharide capsule capable of binding to said composition. 23. A composition according to claim 17, wherein said immune stimulant comprises protamine in a form capable of binding to heparin. 24. A composition according to claim 17, wherein said immune stimulant comprises a heparinase. 25. A composition according to claim 17, wherein said immune stimulant comprises cobra venom factor in a form adapted to enhance production of C3b. 26. A composition according to claim 25, wherein said cobra venom factor is dCVF. 27. A composition according to claim 17, wherein said immune stimulant comprises Nickel in a form adapted to enhance C3 convertase activity. 28. A composition according to claim 17, wherein said immune stimulant comprises sulfated polyanions capable of absorbing Factor H. 29. A composition according to claim 1, wherein polyanions within the composition capable of potentiating Factor H are substantially removed from the composition. 30. An immunogenic composition comprising, an HIV-1 MA polypeptide myristate binding site, said polypeptide consisting of SEQ ID NO.: 1, a pharmaceutically acceptable carrier, and an immune stimulant wherein said immune stimulant comprises cobra venom factor and wherein said composition is capable of inducing a Th1 immune response to HIV-1.

Details for Patent 7,611,712

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989	⤷ Try a Trial	2023-10-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.